Author

Assel T. Stambekova

Observed names: A. Stambekova, Assel Stambekova

Institution: Partners In Health

Observed institutions: Partners In Health, Kazakhstan Academy of Preventive Medicine

ORCID: 0000-0003-4014-7368

Observed ORCID: 0000-0003-4014-7368

OpenAlex ID: A5033293260

Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

2023 · Ismat Lotia Farrukh, Nathalie Lachenal, et al. · Clinical Infectious Diseases · 23

Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

2021 · Shynar M. Maretbayeva, Anar S. Rakisheva, et al. · International Journal of Infectious Diseases · 14

Setting up pharmacovigilance based on available endTB Project data for bedaquiline

2020 · N. Lachenal, C. Hewison, et al. · The International Journal of Tuberculosis and Lung Disease · 11

Clinical best practices for caring for people with expanded resistance to newer TB drugs

2025 · T. Nkomo, Z. Udwadia, et al. · IJTLD OPEN · 9

Cross-Sectional Study of Chronic Obstructive Pulmonary Disease Prevalence Among Smokers, Ex-Smokers, and Never-Smokers in Almaty, Kazakhstan: Study Protocol

2017 · Almaz Sharman, Baurzhan Zhussupov, et al. · JMIR Research Protocols · 5

Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence

2026 · Allison LaHood, James Robins, et al. · American Journal of Epidemiology · 1

Implementation of next-generation sequencing to guide care and public health action in settings with high burden of rifampicin-resistant tuberculosis: 32 stakeholder consensus statements generated using Delphi principles

2026 · Anzaan Dippenaar, Vincent Rennie, et al. · BMJ Public Health

Dietary Intake Analyses for the Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis (PandrTB) Pharmacokinetic Sub-Study of the endTB and endTB-Q Clinical Trials

2026 · Loren Hans, Rina Swart, et al. · Research Square

Corrigendum to ‘Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis’ International Journal of Infectious Diseases Volume 113S1 (2021) S91-S95

2022 · Shynar M. Maretbayeva, Anar S. Rakisheva, et al. · International Journal of Infectious Diseases

Works count: 10

Citation count: 63

H-index: 5

I10-index: 3